… A risk ratio <1 indicates that the immunocompromised participants had a lower risk of
achieving seroconversion after covid-19 vaccination compared with immunocompetent controls. …

Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19. Objectives We …

… the impact of vaccination upon social participation and quality of life. … COVID-19 vaccination
influences social participation in a prospective, multicenter study with immunocompromised …

… Such a control group would increase the validity of our results regarding the influence of the
COVID-19 vaccination on social participation in immunocompromised people and helped to …

… for the treatment of COVID-19 during the last year, we still do not have evidence-based
knowledge on the best therapeutic strategy to treat immunocompromised patients. Most treatment …

… of COVID-19. This article will explore use of immunosuppressive agents and risk for
COVID-19 disease progression in different populations of immunocompromised individuals …

… Serum was collected from participants after completion of their COVID-19 vaccine series
and processed at UPMC’s CLIA-88 accredited Central Lab. The primary outcome was …

… 137 participants had their medication suspended or changed during the study period due
to … a cohort of immunocompromised paediatric patients during the COVID-19 pandemic. We …

… participants with any immunocompromised condition compared with immunocompetent
participants … -CoV-2 naive participants with any immunocompromised condition compared with …

… participants in the original study). None of these participants had previously experienced
COVID-19 … dose of the vaccine, antibody was detectable in 357 participants (54%; 95% CI, 50%-…